1 results match your criteria: "From the Vanderbilt Eye Institute (H.A.[Affiliation]"
A 1-Year Retrospective Case Series of Fluocinolone Acetonide 0.18-mg Injectable Intravitreal Implant in Chronic Uveitis.
Am J Ophthalmol
February 2023
From the Vanderbilt Eye Institute (H.A., A.N., S.G., S.J.K.), Nashville, Tennessee. Electronic address:
Purpose: To evaluate the real-world therapeutic efficacy and safety of the novel, long-acting fluocinolone acetonide 0.18-mg injectable intravitreal implant (FAi) in chronic uveitis.
Design: Retrospective case series.